|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bombonati A and Sgroi DC: The molecular
pathology of breast cancer progression. J Pathol. 223:307–317.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hong W and Dong E: The past, present and
future of breast cancer research in China. Cancer Lett. 351:1–5.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu J, Steeg PS, Price JE, Krishnamurthy S,
Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, et
al: Breast cancer metastasis: Challenges and opportunities. Cancer
Res. 69:4951–4953. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Steeg PS: Targeting metastasis. Nat Rev
Cancer. 16:201–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martinez-Morales PL, Quiroga AC, Barbas JA
and Morales AV: SOX5 controls cell cycle progression in neural
progenitors by interfering with the WNT-beta-catenin pathway. EMBO
Rep. 11:466–472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rescan PY and Ralliere C: A Sox5 gene is
expressed in the myogenic lineage during trout embryonic
development. Int J Dev Biol. 54:913–918. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma S, Chan YP, Woolcock B, Hu L, Wong KY,
Ling MT, Bainbridge T, Webber D, Chan TH, Guan XY, et al: DNA
fingerprinting tags novel altered chromosomal regions and
identifies the involvement of SOX5 in the progression of prostate
cancer. Int J Cancer. 124:2323–2332. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Y, Liu W, Chao T, Zhang Y, Yan X,
Gong Y, Qiang B, Yuan J, Sun M and Peng X: MicroRNA-21
down-regulates the expression of tumor suppressor PDCD4 in human
glioblastoma cell T98G. Cancer Lett. 272:197–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang D, Han S, Wang X, Peng R and Li X:
SOX5 promotes epithelial-mesenchymal transition and cell invasion
via regulation of twist1 in hepatocellular carcinoma. Med Oncol.
32:4612015.PubMed/NCBI
|
|
12
|
Zhang D and Liu S: SOX5 promotes
epithelial-mesenchymal transition in osteosarcoma via regulation of
Snail. J BUON. 22:258–264. 2017.PubMed/NCBI
|
|
13
|
Huang DY, Lin YT, Jan PS, Hwang YC, Liang
ST, Peng Y, Huang CY, Wu HC and Lin CT: Transcription factor SOX-5
enhances nasopharyngeal carcinoma progression by down-regulating
SPARC gene expression. J Pathol. 214:445–455. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pei XH, Lv XQ and Li HX: Sox5 induces
epithelial to mesenchymal transition by transactivation of Twist1.
Biochem Biophys Res Commun. 446:322–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gonzalez ME, Moore HM, Li X, Toy KA, Huang
W, Sabel MS, Kidwell KM and Kleer CG: EZH2 expands breast stem
cells through activation of NOTCH1 signaling. Proc Natl Acad Sci
USA. 111:3098–3103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kleer CG, Cao Q, Varambally S, Shen R, Ota
I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Truax AD, Thakkar M and Greer SF:
Dysregulated recruitment of the histone methyltransferase EZH2 to
the class II transactivator (CIITA) promoter IV in breast cancer
cells. PLoS One. 7:e360132012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wuebben EL and Rizzino A: The dark side of
SOX2: Cancer-a comprehensive overview. Oncotarget. 8:44917–44943.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bulstrode H, Johnstone E, Marques-Torrejon
MA, Ferguson KM, Bressan RB, Blin C, Grant V, Gogolok S, Gangoso E,
Gagrica S, et al: Elevated FOXG1 and SOX2 in glioblastoma enforces
neural stem cell identity through transcriptional control of cell
cycle and epigenetic regulators. Genes Dev. 31:757–773. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu K, Xie F, Gao A, Zhang R, Zhang L,
Xiao Z, Hu Q, Huang W, Huang Q, Lin B, et al: SOX2 regulates
multiple malignant processes of breast cancer development through
the SOX2-miR-181a-5p, miR-30e-5p-TUSC3 axis. Mol Cancer. 16:622017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inoue H, Takahashi H, Hashimura M, Eshima
K, Akiya M, Matsumoto T and Saegusa M: Cooperation of Sox4 with
β-catenin-p300 complex in transcriptional regulation of the slug
gene during divergent sarcomatous differentiation in uterine
carcinosarcoma. BMC Cancer. 16:532016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bilir B, Osunkoya AO, Wiles WG VI,
Sannigrahi S, Lefebvre V, Metzger D, Spyropoulos DD, Martin WD and
Moreno CS: SOX4 is essential for prostate tumorigenesis initiated
by PTEN ablation. Cancer Res. 76:1112–1121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun R, Jiang B, Qi H, Zhang X, Yang J,
Duan J, Li Y and Li G: SOX4 contributes to the progression of
cervical cancer and the resistance to the chemotherapeutic drug
through ABCG2. Cell Death Dis. 6:e19902015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoon TM, Kim SA, Cho WS, Lee DH, Lee JK,
Park YL, Lee KH, Lee JH, Kweon SS, Chung IJ, et al: SOX4 expression
is associated with treatment failure and chemoradioresistance in
oral squamous cell carcinoma. BMC Cancer. 15:8882015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tiwari N, Tiwari VK, Waldmeier L, Balwierz
PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schübeler D, van
Nimwegen E and Christofori G: Sox4 is a master regulator of
epithelial-mesenchymal transition by controlling Ezh2 expression
and epigenetic reprogramming. Cancer Cell. 23:768–783. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hasegawa S, Nagano H, Konno M, Eguchi H,
Tomokuni A, Tomimaru Y, Asaoka T, Wada H, Hama N, Kawamoto K, et
al: A crucial epithelial to mesenchymal transition regulator,
Sox4-Ezh2 axis is closely related to the clinical outcome in
pancreatic cancer patients. Int J Oncol. 48:145–152. 2016.
View Article : Google Scholar : PubMed/NCBI
|
